After nearly four decades of research, Mayo Clinic scientists have revealed the molecular structures of protein kinase C beta (PKCβ), a key protein implicated in cancer, neurological diseases, and metabolic disorders. Their findings, published in the May 21, 2026 edition of Nature Communications, provide the first detailed view of how PKCβ functions at the molecular level and how the breast cancer drug endoxifen can target this protein. [1] These insights offer a new framework for developing more precise therapies for cancer, diabetes, and related conditions.
Protein kinase C (PKC) is a family of serine/threonine kinases critical for cell signaling, growth, and survival, comprising approximately 2% of the human kinome.[2]* PKC isoforms are divided into three subfamilies based on their activation requirements: conventional (α, βI, βII, γ), novel (δ, ε, η, θ), and atypical (λ/ι, ζ).[3][4]
Among them, PKCβ has emerged as a central player in a range of diseases, including cancer, Alzheimer’s disease, metabolic syndrome, and diabetic complications. [5] Scientists have long viewed them as promising drug targets. However, the lack of structural information on full-length human PKC enzymes has long hindered the development of targeted therapies.
Solving a Four-Decade-Long Mystery
Since the discovery of PKC in the 1980s, the field has struggled to determine the structure of full-length human PKC enzymes. [6] Traditional expression systems failed to capture the native conformation necessary for structural analysis. Led by Matthew J. Schellenberg, Ph.D., Mayo Clinic researchers overcame this barrier by expressing PKC enzymes in human cells, yielding high-quality material that enabled the elucidation of the structures of PKCβ1 and PKCβ2. [7][8]
These structural studies revealed how PKCβ remains in an auto-inhibited state and how lipid membranes act as a molecular lever to activate the enzyme. This ‘lipid lever’ mechanism shifts PKCβ from a closed, inactive state to an open, active conformation, exposing its catalytic site and initiating downstream signaling.[9]
PKCβ as a Drug Target: Insights from Endoxifen
PKCβ is highly expressed in tissues such as the brain and adipose tissue and is implicated in regulating cell growth, energy homeostasis, and vascular function. [10]
The breakthrough structural data enabled Mayo Clinic researchers to investigate how endoxifen, a secondary tamoxifen metabolite and potent antiestrogen that binds to estrogen receptor alpha (ERα) at nanomolar concentrations, interacts with PKCβ. Unlike classical inhibitors that compete for the active site, endoxifen binds allosterically, stabilizing PKCβ at membranes and facilitating its degradation. [11] This mechanism is fundamentally distinct from earlier PKC inhibitors and may underlie endoxifen’s unique biological effects.
Implications for Cancer and Precision Medicine
The PKC family comprises 10 isoforms, each with distinct roles in health and disease. Some isoforms promote tumor growth, while others act as tumor suppressors. [12] Understanding the structural basis of PKCβ regulation now allows researchers to design isoform-specific drugs and precisely modulate PKC activity. Mayo Clinic teams are extending their investigations to all PKC family members, aiming to map their structures and therapeutic vulnerabilities.
The implications extend beyond cancer. PKCβ is a key modulator in metabolic diseases. Mice lacking PKCβ are lean, resistant to diet-induced obesity, and show improved insulin sensitivity.[13][14]. In humans, PKCβ activity is linked to insulin resistance, obesity, and vascular complications of diabetes, including retinopathy [15][16]. Pharmacological targeting of PKCβ, either directly or by modulating its regulators, represents a promising avenue for treating metabolic and neurodegenerative diseases.
PKCβ: Molecular Regulation and Metabolic Implications
PKCβ is encoded by a single gene locus that produces two splice variants, PKCβI and PKCβII, with distinct physiological functions [5]. Its activity is regulated by lipid cofactors, phosphorylation, and oxidative stress, which influence both its subcellular localization and signaling output. [8][17][18] In adipose tissue, PKCβ expression increases in response to high-fat diets, and its activation contributes to mitochondrial dysfunction, insulin resistance, and adipose inflammation. [10][19] Conversely, PKCβ-deficient mice show upregulation of genes associated with energy dissipation and brown fat-like properties in white adipose tissue, offering resistance to obesity and hepatic steatosis. [12][13][20]
PKCβ also plays a critical role in angiogenesis, adipocyte differentiation, and vascular endothelial growth factor (VEGF) signaling, linking it to complications such as diabetic retinopathy. [15][21]
The mapping of PKCβ’s structure marks a watershed moment in kinase biology. For the first time, scientists can visualize the full-length enzyme, understand its regulatory mechanisms, and rationally design therapies that selectively target PKCβ and related isoforms. These advances hold promise for precision medicine approaches in cancer, metabolic diseases, and neurodegeneration, fueling renewed interest in targeted therapeutics.
Clinical trials of ruboxistaurin (e.g., LY333531; ruboxistaurin mesylate; Eli Lilly and Company/Takeda), * an orally active, selective PKCβ inhibitor developed by Eli Lilly for the treatment of diabetic retinopathy and related microvascular complications, have shown trends toward improvement in diabetic retinopathy and macular edema, though further studies are ongoing.[16] Several multicenter, randomized clinical trials have evaluated its efficacy and safety:
- In the PKC-DRS and PKC-DRS2 trials, ruboxistaurin demonstrated a reduction in vision loss and progression of diabetic retinopathy compared to placebo, but the results did not achieve all primary endpoints for regulatory approval. [16]
- The US Food and Drug Administration (FDA) issued an approvable letter in 2006, requesting further efficacy data from an additional phase 3 study, which the sponsor did not pursue. As a result, ruboxistaurin remains unapproved for clinical use in the United States or elsewhere.
- Other studies and meta-analyses confirm ruboxistaurin’s benefit in reducing macular edema and microvascular complications, but highlight the need for larger, longer-term trials to establish its clinical utility.[15]
Currently, no other PKCβ-selective inhibitors have advanced to late-stage clinical trials or regulatory approval for diabetic complications, cancer, or neurodegenerative disease. Ongoing research focuses on discovering next-generation PKCβ inhibitors with improved selectivity, bioavailability, and CNS penetration, as well as exploring combination therapies for oncology and metabolic diseases. Large-scale omics studies and biomarker development are expected to guide future trial design and patient selection, building on mechanistic insights from recent breakthroughs in structural biology. Continued research into the molecular mechanisms and downstream targets of PKCβ will be pivotal in transforming these insights into clinical therapies.
__
Note:* The human kinome refers to the complete set of protein kinases encoded within the human genome. It comprises roughly 538 enzymes (518 protein kinases and 20 lipid kinases) that regulate cellular communication and signal transduction. By transferring phosphate groups, they govern processes like metabolism, cell division, and apoptosis, making them vital drug targets.
Note:** Ruboxistaurin mesylate (proposed brand name: Arxxant®; Eli Lilly and Company/Takeda) is an investigational, orally active, selective protein kinase C beta (PKCβ) inhibitor developed by Eli Lilly and Company, primarily for the treatment of diabetic retinopathy. Despite its promising pharmacological profile—demonstrating potent and selective inhibition of PKCβ isoforms and beneficial effects in preclinical models—ruboxistaurin is not FDA-approved for any indication. In February 2006, Eli Lilly submitted a New Drug Application (NDA) for ruboxistaurin. However, in August 2006, the FDA issued an Approvable Letter requesting an additional Phase 3 efficacy trial, estimated to take 5 years. Eli Lilly did not pursue further approval, and as of now, ruboxistaurin remains unapproved in the U.S. Pharmacologically, ruboxistaurin is highly selective for PKCβI and PKCβII (IC50 values of 4.7 nM and 5.9 nM, respectively), with much less effect on other PKC isoforms. It acts as an ATP-competitive inhibitor and has shown efficacy in reducing glucose-induced endothelial dysfunction, inflammation, and microvascular injury in both in vitro and in vivo studies. In animal models, it reduces leukocyte entrapment in retinal vessels and ameliorates diabetic renal and retinal complications. The lack of additional required clinical data to-date has prevented its approval for clinical use.
References
[1] Cong ATQ, Witter TL, Bruinsma ES, Sarkar Bhattacharya S, Jayaraman S, Wyatt SR, Solverson JK, Dugan MB, Paluncic J, Kuffel MJ, Alvey JR, Huynh HV, Wu X, Fields AP, Pandey A, Hawse JR, Goetz MP, Schellenberg MJ. Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ. Nat Commun. 2026 May 21. doi: 10.1038/s41467-026-73413-5. Epub ahead of print. PMID: 42168197.
[2] Parker PJ. Protein kinase C: a structurally related family of enzymes. In: Epand RM, Lester DS, editors. Protein kinase C: current concepts and future perspectives. Ellis Horwood; 1992. p. 3–24.
[3] Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995 Apr;9(7):484-96. PMID: 7737456.
[4] Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem. 1995 Dec 1;270(48):28495-8. doi: 10.1074/jbc.270.48.28495. PMID: 7499357.
[5] Mochly-Rosen D, Khaner H, Lopez J. Identification of intracellular receptor proteins for activated protein kinase C. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3997-4000. doi: 10.1073/pnas.88.9.3997. PMID: 1850844; PMCID: PMC51580.
[6] Ono Y, Kikkawa U, Ogita K, Fujii T, Kurokawa T, Asaoka Y, Sekiguchi K, Ase K, Igarashi K, Nishizuka Y. Expression and properties of two types of protein kinase C: alternative splicing from a single gene. Science. 1987 May 29;236(4805):1116-20. doi: 10.1126/science.3576226. PMID: 3576226.
[7] Parker PJ, Parkinson SJ. AGC protein kinase phosphorylation and protein kinase C. Biochem Soc Trans. 2001 Nov;29(Pt 6):860-3. doi: 10.1042/0300-5127:0290860. PMID: 11709088.
[8] Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J. 2003 Mar 1;370(Pt 2):361-71. doi: 10.1042/BJ20021626. PMID: 12495431; PMCID: PMC1223206.
[9] Newton AC. Lipid activation of protein kinases. J Lipid Res. 2009 Apr;50 Suppl(Suppl):S266-71. doi: 10.1194/jlr.R800064-JLR200. Epub 2008 Nov 24. PMID: 19033211; PMCID: PMC2674703.
[10] Huang W, Bansode R, Mehta M, Mehta KD. Loss of protein kinase Cbeta function protects mice against diet-induced obesity and development of hepatic steatosis and insulin resistance. Hepatology. 2009 May;49(5):1525-36. doi: 10.1002/hep.22815. PMID: 19296465; PMCID: PMC2728215.
[11] Cong ATQ, Witter TL, Bruinsma ES, Sarkar Bhattacharya S, Jayaraman S, Wyatt SR, Solverson JK, Dugan MB, Paluncic J, Kuffel MJ, Alvey JR, Huynh HV, Wu X, Fields AP, Pandey A, Hawse JR, Goetz MP, Schellenberg MJ. Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase Cβ. Nat Commun. 2026 May 21. doi: 10.1038/s41467-026-73413-5. Epub ahead of print. PMID: 42168197.
[12] Kajimura S, Seale P, Spiegelman BM. Transcriptional control of brown fat development. Cell Metab. 2010 Apr 7;11(4):257-62. doi: 10.1016/j.cmet.2010.03.005. PMID: 20374957; PMCID: PMC2857670.
[13] Bansode RR, Huang W, Roy SK, Mehta M, Mehta KD. Protein kinase C deficiency increases fatty acid oxidation and reduces fat storage. J Biol Chem. 2008 Jan 4;283(1):231-236. doi: 10.1074/jbc.M707268200. Epub 2007 Oct 24. PMID: 17962198.
[14] Huang W, Bansode RR, Bal NC, Mehta M, Mehta KD. Protein kinase Cβ deficiency attenuates obesity syndrome of ob/ob mice by promoting white adipose tissue remodeling. J Lipid Res. 2012 Mar;53(3):368-378. doi: 10.1194/jlr.M019687. Epub 2011 Dec 30. PMID: 22210924; PMCID: PMC3276460.
[15] Amadio M, Bucolo C, Leggio GM, Drago F, Govoni S, Pascale A. The PKCbeta/HuR/VEGF pathway in diabetic retinopathy. Biochem Pharmacol. 2010 Oct 15;80(8):1230-7. doi: 10.1016/j.bcp.2010.06.033. Epub 2010 Jul 1. PMID: 20599775.
[16] Aiello LP, et al. Protein kinase C beta inhibition by LY333531 reduces vascular complications in diabetic retinopathy: results of a multicenter trial. (Personal communication).
[17] Rimessi A, Rizzuto R, Pinton P. Differential recruitment of PKC isoforms in HeLa cells during redox stress. Cell Stress Chaperones. 2007 Winter;12(4):291-8. doi: 10.1379/csc-211.1. PMID: 18229448; PMCID: PMC2134791.
[18] Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med. 2000 May 1;28(9):1349-61. doi: 10.1016/s0891-5849(00)00221-5. PMID: 10924854.
[19] Dahlman I, Forsgren M, Sjögren A, Nordström EA, Kaaman M, Näslund E, Attersand A, Arner P. Downregulation of electron transport chain genes in visceral adipose tissue in type 2 diabetes independent of obesity and possibly involving tumor necrosis factor-alpha. Diabetes. 2006 Jun;55(6):1792-9. doi: 10.2337/db05-1421. PMID: 16731844.
[20] Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev. 2013 Feb 1;27(3):234-50. doi: 10.1101/gad.211649.112. PMID: 23388824; PMCID: PMC3576510.
[21] Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform’s action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA. 2002;99:721–726.
[22] PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005 Jul;54(7):2188-97. doi: 10.2337/diabetes.54.7.2188. PMID: 15983221.
Featured image: 2017 – 2026 © Mayo Clinic. used with permission.
DOI
